Literature DB >> 8194840

Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

D Parker1, D L Alison, D L Barnard, J A Child, G Dovey, J Farish, D R Norfolk, C J O'Brien, L A Parapia, J Sharp.   

Abstract

Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 of these patients the bone marrow was the only site of extranodal involvement. Univariate survival analysis showed that the sum of involved sites was more discriminatory than Ann Arbor stage. Analysis by site of involvement showed that the liver and other intraabdominal sites were associated with worse survival than involvement of peripheral lymph nodes. Bone marrow and spleen involvement were not significantly associated with short survival. Increasing age at presentation was strongly associated with shorter survival and was also inversely correlated with serum albumin. Both low absolute lymphocyte count (< 1.0 x 10(9)/l), low serum IgG level (< 10 g/l) and low total immunoglobulins on presentation were significantly associated with short survival. Multivariate analysis showed that age, serum albumin and number of involved sites gave the best survival prediction. The sum of involved sites, immunoglobulin level and absolute lymphocyte count may be useful objective markers of prognosis in low-grade non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194840     DOI: 10.1002/hon.2900120104

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  2 in total

1.  Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma.

Authors:  Shogo Kumagai; Masaharu Tashima; Jun Fujikawa; Makoto Iwasaki; Yoshihiro Iwamoto; Yuki Sueki; Akiko Fukunaga; Soshi Yanagita; Momoko Nishikori; Akifumi Takaori-Kondo; Nobuyoshi Arima
Journal:  Int J Hematol       Date:  2014-04-23       Impact factor: 2.490

2.  A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk.

Authors:  H Dean Hosgood; Mark P Purdue; Sophia S Wang; Tongzhang Zheng; Lindsay M Morton; Qing Lan; Idan Menashe; Yawei Zhang; James R Cerhan; Andrew Grulich; Wendy Cozen; Meredith Yeager; Theodore R Holford; Claire M Vajdic; Scott Davis; Brian Leaderer; Anne Kricker; Maryjean Schenk; Shelia H Zahm; Nilanjan Chatterjee; Stephen J Chanock; Nathaniel Rothman; Patricia Hartge; Bruce Armstrong
Journal:  Br J Haematol       Date:  2011-01-20       Impact factor: 6.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.